JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Guardado en:
Autores principales: | Nobukazu Fujimoto, Yosuke Miyamoto, Sae Wada, Katsuyuki Hotta, Toshiyuki Kozuki, Keisuke Aoe, Jun Sakurai, Michihiro Yoshida, Daijiro Harada |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/af8197ea96ff4fda8b8b228a37b81135 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study
por: Cova E, et al.
Publicado: (2019) -
Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
por: Hiroto Yoneda, et al.
Publicado: (2021) -
Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma
por: Camillo Porta, et al.
Publicado: (2008) -
Cytomegalovirus infection in malignant pleural mesothelioma.
por: DeVon Hunter-Schlichting, et al.
Publicado: (2021) -
Modern management of malignant pleural mesothelioma
por: Patel SC, et al.
Publicado: (2016)